Loading
A phase 3 trial of Dato-DXd in HR-positive / HER2-negative breast cancer, run by AstraZeneca, now recruiting.
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer is a phase 3 interventional study registered as NCT07205822 by AstraZeneca, with 100 participants planned, started 2025-10-30 and due to reach its primary completion in 2028-02-02. Interventions recorded: Dato-DXd.
Shares AstraZeneca, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Daiichi Sankyo and the tag pipeline.
Shares Daiichi Sankyo and the tag pipeline.
Shares Daiichi Sankyo, AstraZeneca, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares Daiichi Sankyo, AstraZeneca and the tag pipeline.